Zobrazeno 1 - 10
of 81
pro vyhledávání: '"National Cooperative Growth Study"'
Autor:
Abdelkader Rahmaoui, Benjamin Trzaskoma, Theresa Johanna Lehrian, Gunnar Blumenstock, Gerhard Binder, Elisa Hoffmann, Thomas Reinehr
Publikováno v:
Clinical endocrinologyREFERENCES. 94(2)
OBJECTIVE Constitutional delay of growth and puberty (CDGP) is a tempo variant with a good prognosis. Healthy late-maturing adolescents grow slower than postulated by age-related references, and therefore, CDGP is frequently confused with growth horm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0496f06024094795af3a2c4d182ad009
https://pubmed.ncbi.nlm.nih.gov/33113160
https://pubmed.ncbi.nlm.nih.gov/33113160
Publikováno v:
The Journal of Pediatrics. 167:1389-1396
ObjectiveTo examine whether attention-deficit/hyperactivity disorder (ADHD) stimulant medication modified the linear growth response to growth hormone (GH) treatment in children enrolled in the American Norditropin Studies: Web-Enabled Research Progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2533b882f9d2be92756c9415ec03408
https://doi.org/10.1016/j.jpeds.2015.08.036
https://doi.org/10.1016/j.jpeds.2015.08.036
Autor:
Sandra Pekic, Vera Popovic
Publikováno v:
European Journal of Endocrinology. 169:R89-R97
It has been difficult to identify factors that affect the risk of cancer, but we know that people are at higher risk as they get older, or if they have a strong family history of cancer. The potential influence of environmental and behavioral factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::870a4e52e35cacdaa85dd6863d7880ac
https://doi.org/10.1530/eje-13-0389
https://doi.org/10.1530/eje-13-0389
Autor:
Sally Radovick, Sara A. DiVall
Publikováno v:
Current Pediatrics Reports. 1:128-132
The availability of recombinant human growth hormone (rGH) for treatment of growth disorders has provided an unlimited supply for replacement in patients with growth hormone insufficiency but also for short stature due to Turner syndrome, renal failu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d4225709f0185f60c28bcc03c1be6f2
https://doi.org/10.1007/s40124-013-0009-5
https://doi.org/10.1007/s40124-013-0009-5
Publikováno v:
Journal of neurosurgery. Pediatrics. 18(4)
OBJECTIVE The object of this study was to establish recurrence rates in patients with craniopharyngioma postoperatively treated with recombinant human growth hormone (rhGH) as a basis for determining the risk of rhGH therapy in the development of rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81046881c0cf29a464f1c16844e9d27
https://pubmed.ncbi.nlm.nih.gov/27286443
https://pubmed.ncbi.nlm.nih.gov/27286443
Publikováno v:
The Journal of Pediatrics. 157:265-270
Objective To assess the incidence of cancer in patients treated with growth hormone (GH) in KIGS—the Pfizer International Growth Database—without cancer or any other condition in medical history known to increase the risk of cancer. Study design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a881b3bd437a238ec429c6b6a235aa22
https://doi.org/10.1016/j.jpeds.2010.02.028
https://doi.org/10.1016/j.jpeds.2010.02.028
First-year response to rhGH therapy in children with CKD: a National Cooperative Growth Study Report
Autor:
Barbara Lippe, Bradley A. Warady, D. Aaron Davis, Ron G. Rosenfeld, James Frane, Rita D. Swinford, John D. Mahan
Publikováno v:
Pediatric Nephrology. 25:1125-1130
A clear definition of the appropriate growth response during recombinant human growth hormone (rhGH) treatment has never been established in the pediatric chronic kidney disease (CKD) population. We present here data from Genentech's National Coopera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::875ac07656d5871a6df05540cf21dffe
https://doi.org/10.1007/s00467-010-1450-0
https://doi.org/10.1007/s00467-010-1450-0
Autor:
David B. Allen
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 95:52-55
Twenty-five years ago, the pediatric endocrinology community was stunned by news of Creutzfeldt-Jakob disease transmitted by treatment with pituitary-derived GH (pit-GH). With remarkable serendipity, recombinant DNA-derived human GH (rhGH) became ava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e73f5e75c7817adde7a62958f67000b9
https://doi.org/10.1210/jc.2009-2364
https://doi.org/10.1210/jc.2009-2364
Autor:
Barbara Lippe, Katrina L. Parker, Andrew R. Hoffman, Rita D. Swinford, Thomas Maneatis, Jennifer J. Bell
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 95:167-177
Between 1985 and 2006, the National Cooperative Growth Study (NCGS) monitored the safety and efficacy of recombinant human growth hormone (rhGH) in 54,996 children.Enrolled patients were followed until rhGH discontinuation. Investigators submitted ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d678cadaac7d7ccd80b29d3b2d71319
https://doi.org/10.1210/jc.2009-0178
https://doi.org/10.1210/jc.2009-0178
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 93:352-357
Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed.The objective of this study was to present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7779b8334e9dc784fd4e36adad9dac37
https://doi.org/10.1210/jc.2007-1581
https://doi.org/10.1210/jc.2007-1581